Tier 2 — strong

The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial

Mojtaba Shohan, Roohangiz Nashibi, Mohammad-Reza Mahmoudian-Sani, Farhad Abolnezhadian, Mehri Ghafourian, Seyed Mohammad Alavi, Asaad Sharhani, Ali Khodadadi
European journal of pharmacology 2022 914:174615

Bibliography

PubMed
PMID 34863994
PubMed Central
PMC8638148
DOI
10.1016/j.ejphar.2021.174615
Funding
Reported funding/support: This work was supported by the Deputy of Research and Technology of 10.13039/501100005001Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IRAN. Grant number: U-99020.
Competing interests
Reported disclosure: ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Study snapshot

DesignRandomized open-label adjunctive trial
ModelHuman intervention research
Sample60 hospitalized adults with severe COVID-19
InterventionQuercetin 1,000 mg/day plus remdesivir or favipiravir versus antivirals alone
Duration7 days
EndpointsInflammatory measures; Events and survival

What the study showed, in plain terms

Published in 2022, this source examined immunity and respiratory health. Design: Randomized open-label adjunctive trial. Sample/model: 60 hospitalized adults with severe COVID-19. The exposure or intervention was Quercetin 1,000 mg/day plus remdesivir or favipiravir versus antivirals alone. Follow-up or treatment period: 7 days.

Some inflammatory and biochemical measures improved, with a discharge signal. Mortality and intensive-care comparisons were not significant.

Small unblinded adjunctive study. Biomarker changes do not establish a mortality benefit or routine infection treatment.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Immune Health, Colds and COVID-19. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Some inflammatory and biochemical measures improved, with a discharge signal.
  • Mortality and intensive-care comparisons were not significant.
  • The recorded outcome domains were Inflammatory measures; Events and survival.
  • The result applies to the tested exposure: Quercetin 1,000 mg/day plus remdesivir or favipiravir versus antivirals alone; 7 days.

What this study can and cannot tell us

  • Small unblinded adjunctive study. Biomarker changes do not establish a mortality benefit or routine infection treatment.
  • Without a sufficiently blinded concurrent control, time effects, expectations, co-interventions and regression toward the mean can explain part of an apparent improvement.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Immune Preconditioning with Oral Quercetin Supplement and COVID-19 mRNA Vaccine Responses: A Randomized, Double-Blind, Placebo-Controlled Trial
Shokichi Takahama et al. · The Journal of nutrition · 2026
Tier 2
Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19-Results From a Pilot Open-Label, Randomized Controlled Trial
Amjad Khan et al. · Frontiers in pharmacology · 2022
Tier 2
Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial
Francesco Di Pierro et al. · Frontiers in pharmacology · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology